or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVS D -0.07 0.55
    ABBV A -0.07 0.50

    Represented by ETF Holdings

    Keywords: Eye Care Products Pharmaceutical Active Pharmaceutical Ingredients Adalimumab Advanced Prostate Cancer Anemia Animal Health Antibiotics Atopic Dermatitis Autoimmune Disease Biotechnology Blood Cancers Blood Test Chronic Idiopathic Constipation Combination Drugs Constipation Contact Lens Contact Lenses Crohn's Disease Depressive Disorder
    Industries: Drug Manufacturers - Major

    Recent News for PowerShares DWA Developed Market Technical Leaders Portfolio & its Holdings

    Date Stock Title
    Oct 2 ABBV AbbVie: $200 Peak (Rating Downgrade)
    Oct 2 NVS Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
    Oct 2 ABBV AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation
    Oct 2 ABBV Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
    Oct 2 ABBV 5 Best Dividend Growth Stocks to Buy in October
    Oct 2 ABBV Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
    Oct 2 ABBV Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
    Oct 1 ABBV Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
    Oct 1 NVS US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
    Oct 1 ABBV AbbVie withdraws Exviera from EU market for commercial reasons
    Oct 1 NVS Teva launches first U.S. generic against Novartis antidiarrheal Sandostatin LAR
    Oct 1 ABBV AbbVie to Host Third-Quarter 2024 Earnings Conference Call
    Sep 30 NVS Top Research Reports for Apple, Tesla & T-Mobile US
    Sep 30 NVS Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
    Sep 30 ABBV AbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 Years
    Sep 30 ABBV AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
    Sep 30 ABBV Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?
    Sep 30 NVS Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
    Sep 30 ABBV Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
    Sep 30 ABBV 15 Best Dividend Stocks for Lifelong Passive Income
    The PowerShares DWA Developed Markets Momentum Portfolio (Fund) is based on the Dorsey Wright® Developed Markets Technical Leaders Index ND (Index). The Fund will normally invest at least 80% of its total assets in securities of developed economies within Dorsey, Wright & Associates, LLC's classification definition, excluding US companies listed on a US stock exchange. This Index includes approximately 100 companies that possess powerful relative strength characteristics and are domiciled in developed markets including, but not limited to Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland and the United Kingdom. The Index excludes US companies listed on a US stock exchange. The Index is computed using the net return, which withholds applicable taxes for non-resident investors. The Fund and the Index are rebalanced and reconstituted quarterly. Effective on or about Oct. 4, 2013, the name of the Fund changed from PowerShares DWA Developed Markets Technical Leaders Portfolio to PowerShares DWA Developed Markets Momentum Portfolio
    Exchange Traded Fund ETF Exchange Traded Funds Invesco Powershares Relative Strength Leaders Index Nasdaq 100 Settlement Index
    Back to the Main PIZ Page...